AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 159 filers reported holding AGIOS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.1%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,259,692 | -16.5% | 374,129 | -4.4% | 0.00% | 0.0% |
| Q2 2023 | $11,086,345 | +55.3% | 391,467 | +26.0% | 0.00% | 0.0% |
| Q1 2023 | $7,138,663 | -30.6% | 310,782 | -15.2% | 0.00% | 0.0% |
| Q4 2022 | $10,291,852 | +30.2% | 366,519 | +31.1% | 0.00% | 0.0% |
| Q3 2022 | $7,907,000 | -14.3% | 279,531 | -32.8% | 0.00% | 0.0% |
| Q2 2022 | $9,225,000 | -4.1% | 416,136 | +25.9% | 0.00% | 0.0% |
| Q1 2022 | $9,622,000 | +13.5% | 330,531 | +28.1% | 0.00% | 0.0% |
| Q4 2021 | $8,477,000 | +4.2% | 257,936 | +46.3% | 0.00% | 0.0% |
| Q3 2021 | $8,136,000 | -48.2% | 176,293 | -38.1% | 0.00% | -50.0% |
| Q2 2021 | $15,693,000 | -16.6% | 284,768 | -21.9% | 0.00% | -33.3% |
| Q1 2021 | $18,817,000 | +95.5% | 364,394 | +64.0% | 0.00% | +200.0% |
| Q4 2020 | $9,627,000 | -38.0% | 222,180 | -49.9% | 0.00% | -66.7% |
| Q3 2020 | $15,532,000 | +478.0% | 443,708 | +782.9% | 0.00% | +200.0% |
| Q2 2020 | $2,687,000 | -38.1% | 50,256 | -58.9% | 0.00% | 0.0% |
| Q1 2020 | $4,342,000 | -40.8% | 122,384 | -20.4% | 0.00% | -50.0% |
| Q4 2019 | $7,338,000 | +886.3% | 153,669 | +568.4% | 0.00% | – |
| Q3 2019 | $744,000 | -81.2% | 22,989 | -71.1% | 0.00% | -100.0% |
| Q2 2019 | $3,967,000 | +0.6% | 79,556 | +36.1% | 0.00% | 0.0% |
| Q1 2019 | $3,942,000 | +8.7% | 58,449 | -25.7% | 0.00% | 0.0% |
| Q4 2018 | $3,628,000 | -5.8% | 78,686 | +57.5% | 0.00% | 0.0% |
| Q3 2018 | $3,853,000 | -48.7% | 49,949 | -44.0% | 0.00% | -50.0% |
| Q2 2018 | $7,514,000 | +34.4% | 89,200 | +30.5% | 0.00% | 0.0% |
| Q1 2018 | $5,592,000 | +78.4% | 68,373 | +24.7% | 0.00% | +100.0% |
| Q4 2017 | $3,135,000 | -54.4% | 54,839 | -46.7% | 0.00% | -50.0% |
| Q3 2017 | $6,869,000 | +75.3% | 102,912 | +35.1% | 0.00% | +100.0% |
| Q2 2017 | $3,919,000 | -47.8% | 76,175 | -40.8% | 0.00% | 0.0% |
| Q1 2017 | $7,512,000 | +7.3% | 128,670 | -23.3% | 0.00% | 0.0% |
| Q4 2016 | $6,998,000 | +35.1% | 167,744 | +71.0% | 0.00% | -50.0% |
| Q3 2016 | $5,181,000 | +15.7% | 98,083 | -8.3% | 0.00% | 0.0% |
| Q2 2016 | $4,479,000 | -7.7% | 106,904 | -10.6% | 0.00% | 0.0% |
| Q1 2016 | $4,853,000 | -46.4% | 119,530 | -14.3% | 0.00% | -33.3% |
| Q4 2015 | $9,058,000 | -8.8% | 139,533 | -0.8% | 0.00% | -25.0% |
| Q3 2015 | $9,928,000 | -46.4% | 140,640 | -15.7% | 0.00% | -33.3% |
| Q2 2015 | $18,536,000 | +4.6% | 166,776 | -11.3% | 0.01% | -14.3% |
| Q1 2015 | $17,724,000 | -31.6% | 187,941 | -18.7% | 0.01% | -22.2% |
| Q4 2014 | $25,908,000 | +100.8% | 231,236 | +10.0% | 0.01% | +80.0% |
| Q3 2014 | $12,903,000 | +33.1% | 210,309 | -0.6% | 0.01% | +25.0% |
| Q2 2014 | $9,693,000 | +22.9% | 211,524 | +5.0% | 0.00% | +33.3% |
| Q1 2014 | $7,890,000 | +67.9% | 201,501 | +2.7% | 0.00% | +50.0% |
| Q4 2013 | $4,699,000 | -40.6% | 196,199 | -30.6% | 0.00% | -50.0% |
| Q3 2013 | $7,910,000 | – | 282,907 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |